Fujirebio Europe launches the Lumipulse® G 25-OH Vitamin D, a sensitive two-step sandwich assay

“Vitamin D deficiency is a growing public healthcare problem in adult populations and among elderly institutionalized patients. Our novel two-step sandwich assay improves the standard for Vitamin D testing”, said Christiaan De Wilde, CEO of Fujirebio Europe. “It does not require any separate pretreatment steps or auxiliary solutions and still effectively ensures the release of Vitamin D from its binding protein. The assay time is only 25 minutes allowing for very fast result time. With this new test we are confident that we will be helping even more laboratories across Europe solve their routine testing needs.”

The Lumipulse^® G 25-OH Vitamin D assay further completes the panel of tests available for the LUMIPULSE^® G1200 system.

This product is not available in the USA and in Canada.

About Vitamin D deficiency
Vitamin D is a fat-soluble, secosteroid hormone precursor. In humans, the most abundant forms are Vitamin D3 (cholecalciferol), followed by Vitamin D2 (ergocalciferol), known together as calciferol. Calciferol primarily undergoes hydroxylation in the liver to 25-OH Vitamin D (calcidiol), the major circulating form of vitamin D. The serum or plasma level of 25-OH Vitamin D is recognized as the most reliable indicator of vitamin D sufficiency.  A second hydroxylation in the kidneys of a small amount of 25-OH Vitamin D produces 1,25(OH)₂ Vitamin D (calcitriol).  Calcitriol regulates calcium and phosphate blood concentrations through amongst other intestinal absorption.

Vitamin D deficiency was first discovered in the childhood disease rickets. Since then, deficiency has been linked to various other medical conditions other than bone metabolism.   Examples include, but are not limited to, adult osteomalacia, increased risk for fractures, secondary hyperparathyroidism, autoimmune diseases, diabetes, certain cancers, and cardiovascular problems. 

About Fujirebio
Fujirebio is a leading international healthcare company with a strong focus on high quality in vitro diagnostics (IVD) testing solutions. Founded more than 60 years ago in Japan, the company is today recognized as the world-wide market leader in oncology for both routine and novel markers and has a strong reputation in Japan in infectious disease testing in hospitals, clinical labs and blood banks. Over the last 20 years Fujirebio has been committed to bringing solid and successful automated immunoassay testing solutions and state of the art chemiluminescent assay products to the market. Under the name Innogenetics (now Fujirebio Europe) the company has also been pioneering the field of molecular diagnostics and multiparameter testing. The company is today one of the world leaders in strip-based diagnostics solutions.

The product lines range from specialized manual testing to fully automated routine testing and they cover disease fields such as infectious, oncology, genetic testing, thyroid, fertility, tissue typing, neurodegeneration and bone.

Fujirebio is a subsidiary of Japan-based Miraca Holdings (listed in the Tokyo Stock Exchange - MRCHF) and counts more than 1.100 employees working in Asia, Europe and America, including subsidiaries. For more information about Fujirebio please visit www.fujirebio.com/english or www.fujirebio-europe.com.